SCHEMBL10243010

SCHEMBL10243010

CCOCCCc1cccc(-c2ccco2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.54
PSMB5 P28074 3/20 0.43
TAAR1 Q96RJ0 1/20 0.40
KEAP1 Q14145 1/20 0.39
EGFR P00533 1/20 0.38
FDFT1 P37268 1/20 0.38
KDM4E B2RXH2 6/20 0.36
ALDH1A1 P00352 5/20 0.36
GLA P06280 1/20 0.36
POLB P06746 1/20 0.36
RECQL P46063 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CETP P11597 1/20 0.35
RAB9A P51151 4/20 0.35
HPGD P15428 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HSD17B10 Q99714 3/20 0.35
NPC1 O15118 2/20 0.35
TSHR P16473 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14048817 0.84 PRMT6 (0.60) PRMT6PSMB5TAAR1KEAP1EGFR
SCHEMBL10245034 0.81 PRMT6 (0.64) PRMT6PSMB5TAAR1KEAP1EGFR
SCHEMBL14141440 0.77 PRMT6 (0.68) PRMT6PSMB5TAAR1KEAP1KDM4E
SCHEMBL4137181 0.75 PRMT6 (0.50) PRMT6PSMB5KEAP1KDM4EALDH1A1
SCHEMBL1346211 0.74 PRMT6 (0.59) PRMT6PSMB5TAAR1KEAP1KDM4E
SCHEMBL1347949 0.74 PRMT6 (0.59) PRMT6PSMB5TAAR1KEAP1KDM4E
SCHEMBL14234021 0.74 CYP4F2 (0.43) KDM4EALDH1A1POLBTDP1L3MBTL1
SCHEMBL12133815 0.74 PRMT6 (0.59) PRMT6PSMB5TAAR1KEAP1
SCHEMBL16248161 0.72 TAAR1 (0.52) TAAR1KDM4EALDH1A1RAB9ASMN1; SMN2
SCHEMBL20463165 0.71 SMN1; SMN2 (0.40) PRMT6TAAR1KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PRMT6 1751/4885PSMB5 3215/4885TAAR1 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.